NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology

GlobeNewswire
2025.10.06 13:02
portai
I'm PortAI, I can summarize articles.

SANTA ANA, Calif., Oct. 06, 2025 ( GLOBE NEWSWIRE ) -- NKGen Biotech, Inc. ( OTC: NKGN ) ( "NKGen" or the "Company" ) , a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ( "NK" ) cell therapeutics, today ...

Source: GlobeNewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer